Corvus Pharmaceuticals
CRVS
47 hedge funds and large institutions have $25.4M invested in Corvus Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 13 closing their positions.
33% more call options, than puts
Call options by funds: $80K | Put options by funds: $60K
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.86% less ownership
Funds ownership: 58.87% → 55.01% (-3.9%)
18% less funds holding
Funds holding: 57 → 47 (-10)
44% less capital invested
Capital invested by funds: $44.9M → $25.4M (-$19.6M)
69% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
+$627K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$245K |
| 3 |
TI
Telemetry Investments
New York
|
+$212K |
| 4 |
Renaissance Technologies
New York
|
+$75.8K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$24.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.22M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$837K |
| 3 |
PVI
Pura Vida Investments
New York
|
-$813K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$496K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$229K |
CRVS Hedge Fund Activity: Q2 2022 in Review
47 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q2 2022, worth a combined $25.4M — down 44% from $44.9M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CRVS and 4 opened new positions — a net loss of 9 holders — while 10 trimmed existing stakes and 13 added.
The largest buyer was CHI Advisors, adding an estimated $627K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.22M sold.
- 47 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q2 2022, down from 57 in Q1 2022.
- Funds reported $25.4M of Corvus Pharmaceuticals stock for Q2 2022, down 44% quarter-over-quarter.
- 4 funds opened new Corvus Pharmaceuticals positions in Q2 2022 and 13 closed out, a net change of -9 holders.
- The largest Corvus Pharmaceuticals buyer in Q2 2022 was CHI Advisors, an estimated $627K added.
- The largest Corvus Pharmaceuticals seller in Q2 2022 was Point72 Asset Management, an estimated $1.22M sold.
Based on aggregated 13F filings for Q2 2022.